A Dosimetric Planning Study Comparing Intensity-modulated Radiotherapy with Four-field Conformal Pelvic Radiotherapy for the Definitive Treatment of Cervical Carcinoma

Clinical Oncology

Volumn 24, Issue 4, 2012, Pages

  Forrest, J ^a,b   Presutti, J ^a   Davidson, M ^a   Hamilton, P ^c   Kiss, A ^c   Thomas, G ^a,b  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Cervix cancer; IMRT; Organ motion; Organs at risk; Target definition

Indexed keywords

ARTICLE; BLADDER; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; FEMALE; FOUR FIELD CONFORMAL PELVIC RADIOTHERAPY; HISTOGRAM; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PRIORITY JOURNAL; RADIATION DOSE; RECTUM; SIGMOID; SMALL INTESTINE; TREATMENT PLANNING; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

FEMALE; HUMANS; PELVIS; RADIOMETRY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RESEARCH DESIGN; UTERINE CERVICAL NEOPLASMS;

EID: 84858798424     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2011.06.008     Document Type: Article

References (39)

1. Staffurth J. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol 2010, 22:643-657.
2. Veldeman L., Madani I., Hulstaert F. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008, 9:367-375.
3. Randall M., Ibbott G.S. Intensity-modulated radiation for gynaecologic cancers: pitfalls, hazards and cautions to be considered. Semin Radiat Oncol 2006, 16(3):138-143.
4. Monk B.J., Tewari K.S., Koh W.-J. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol 2007, 25:2952-2965.
5. Dimopoulos J., Schirl G., Baldinger A., Helbich T.H., Potter R. MRI assessment of cervical cancer for adaptive radiotherapy. Strahlenther Onkol 2009, 185:282-287.
6. Dimopoulos J., Schard G., Berger D., et al. Systematic evaluation of MRI findings in different stages of treatment of cervical cancer: potential of MRI on delineation of target, pathoanatomical structures and organs at risk. Int J Radiat Oncol Biol Phys 2006, 64:1380-1388.
7. Beadle B.M., Jhingran A., Salehpour M., Sam M., Iyer R., Eifel P.J. Cervix regression and motion during the course of external beam chemoradiation for cervical cancer. Int J Radiat Oncol Biol Phys 2009, 73(1):235-241.
8. Van de Bunt L., Jurgenliemk-Schulz I.M., de Kort G.A.P., Roesink J.M., Tersteeg R.J.H.A., van der Heide U.A. Motion and deformation of the target volumes during IMRT for cervical cancer: what margins do we need?. Radiother Oncol 2008, 88(2):233-240.
9. Taylor A., Powell M.E.B. An assessment of interfraction uterine and cervical motion: implications for radiotherapy target volume definition in gynaecological cancer. Radiother Oncol 2008, 88:250-257.
10. Chan P., Dinniwell R., Haider M.A., et al. Inter- and intrafractional tumour and organ movement in patients with cervical cancer undergoing radiotherapy: a cinematic-MRI point-of-interest study. Int J Radiat Oncol Biol Phys 2008, 70:1507-1515.
11. Vale C. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008, 26:5802-5812.
12. Kirwan J.M., Symonds P., Green J.A., Tierney J., Collingwood M., Williams C.J. A systemic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 2003, 68:217-226.
13. Eifel P.J., Levenback C., Wharton T., Oswald M.J. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1995, 32:1289-1300.
14. Forrest J., Ackerman I., Barbera L., et al. Patient outcome study of concurrent chemoradiation, external beam radiotherapy, and high-dose rate brachytherapy in locally advanced carcinoma of the cervix. Int J Gynecol Cancer 2010, 20:1074-1078.
15. Scholten A., van Putten W., Beerman H., Creutzberg C. Postoperative radiotherapy for stage 1 endometrial cancer: long-term outcome of the randomised PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005, 63:834-838.
16. Lim K., Small W., Portelance L., et al. Development of RTOG consensus guidelines for definitive IMRT cervix cancer 2009, 2009 OPA. Poster Presentation Edition, Chicago.
17. Lim K., Small W., Portelance L., Creutzberg C. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys 2011, 79:348-355.
18. Williams M.V., Cooper T., Mackay R., Staffurth J., Routsis D., Burnet D. The implementation of intensity modulated radiotherapy in the UK. Clin Oncol 2010, 22:623-628.
19. Taylor A., Rockall A.G., Powell M.E.B. An atlas of the pelvic lymph node regions to aid radiotherapy target volume definition. Clin Oncol 2007, 19:542-550.
20. Taylor A., Rockall A.G., Reznek R.H., Powell M.E.B. Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005, 63:1604-1612.
21. Mell L.K., Tiryaki H., Ahn K.-H., Mundt A., Roeske J., Aydogan B. Dosimetric comparison of bone marrow sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys 2008, 71:1504-1510.
22. Mell L.K., Kochanski J., Roeske J., et al. Dosimetric predictors of acute haematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66:1356-1365.
23. http://radium.wustl.edu/CERR/about.php.
24. D'Souza W.D., Rosen I. Non tumour integral dose variation in conventional radiotherapy treatment planning. Med Phys 2003, 30:2065-2071.
25. Roeske J., Lujan A., Rotmensch J., Waggoner S., Yamada S.D., Mundt A.J. Intensity-modulated whole pelvic radiation therapy in patients with gynaecologic malignancies. Int J Radiat Oncol Biol Phys 2000, 48:1613-1621.
26. Van de Bunt L., Van der Heide U.A., Ketelaars M., De Kort G.A.P., Jurgenliemk-Schulz I.M. Conventional, conformal and intensity-modulated radiation treatment planning of external beam radiotherapy for cervical cancer: the impact of tumour regression. Int J Radiat Oncol Biol Phys 2006, 64:189-196.
27. Taylor A., Powell M.E.B. Conformal and intensity-modulated radiotherapy for cervical cancer. Clin Oncol 2008, 20:417-425.
28. Georg P., Georg D., Hillbrand M., Kirisits C., Potter R. Factors influencing bowel sparing in intensity modulated whole pelvic radiotherapy for gynaecological malignancies. Radiother Oncol 2006, 80:19-26.
29. Lim K., Kelly V., Stewart J., Xie J., Milosevic M. Pelvic radiotherapy for cancer of the cervix: is what you plan actually what you deliver?. Int J Radiat Oncol Biol Phys 2009, 74:304-312.
30. Kwon J.W., Huh S.J., Yoon Y.C., Choe B.K. Pelvic bone complications after radiation therapy of uterine cervical cancer: evaluation with MRI. Am J Roentgenol 2008, 191:987-994.
31. Ikushima H., Osaki K., Furuntani S., Yamashita K., Nishitani H. Pelvic bone complications following radiation therapy of gyneacologic malignancies: clinical evaluation of radiation-induced pelvic insufficiency fractures. Gynaecol Oncol 2006, 103:1100-1104.
32. Suit H., Goldberg S., Niemierko A. Secondary carcinogenesis in patients treated with radiation. A review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat Res 2007, 167:12-42.
33. Trott K.-R. Can we reduce the incidence of second primary malignancies occurring after radiotherapy?. Radiother Oncol 2009, 91:1-3.
34. Tubiana T. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol 2009, 91:4-15.
35. Xu X.G., Bednarz B., Paganetti H. A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. Phys Med Biol 2008, 53:R193-241.
36. Mundt A., Lujan A., Rotmensch J., et al. Intensity-modulated whole pelvic radiotherapy in women with gynaecologic malignancies. Int J Radiat Oncol Biol Phys 2002, 52:1330-1337.
37. Mundt A., Mell L.K., Roeske J. Preliminary analysis of chronic gastrointestinal toxicity in gynaecological patients treated with intensity-modulated whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2003, 56:1354-1360.
38. Mundt A., Roeske J., Lujan A., et al. Initial clinical experience with intensity-modulated whole pelvis radiation therapy in women with gynaecological malignancies. Gynaecol Oncol 2001, 82:456-463.
39. Lujan A., Mundt A., Yamada S.D., Rotmensch J., Roeske J. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynaecological patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2003, 57:516-521.